Role of biomarkers and molecular signaling pathways in acute lung injury
Pakter Niri,Achintya Saha,Subramanyam Polopalli,Mohit Kumar,Sanghita Das,Pronobesh Chattopadhyay
DOI: https://doi.org/10.1111/fcp.12987
2024-01-27
Fundamental and Clinical Pharmacology
Abstract:Background Acute lung injury (ALI) is caused by bacterial, fungal, and viral infections. When pathogens invade the lungs, the immune system responds by producing cytokines, chemokines, and interferons to promote the infiltration of phagocytic cells, which are essential for pathogen clearance. Their excess production causes an overactive immune response and a pathological hyper‐inflammatory state, which leads to ALI. Until now, there is no particular pharmaceutical treatment available for ALI despite known inflammatory mediators like neutrophil extracellular traps (NETs) and reactive oxygen species (ROS). Objectives Therefore, the primary objective of this review is to provide the clear overview on the mechanisms controlling NETs, ROS formation, and other relevant processes during the pathogenesis of ALI. In addition, we have discussed the significance of epithelial and endothelial damage indicators and several molecular signaling pathways associated with ALI. Methods The literature review was done from Web of Science, Scopus, PubMed, and Google Scholar for ALI, NETs, ROS, inflammation, biomarkers, Toll‐ and nucleotide‐binding oligomerization domain (NOD)‐like receptors, alveolar damage, pro‐inflammatory cytokines, and epithelial/endothelial damage alone or in combination. Results This review summarized the main clinical signs of ALI, including the regulation and distinct function of epithelial and endothelial biomarkers, NETs, ROS, and pattern recognition receptors (PRRs). Conclusion However, no particular drugs including vaccine for ALI has been established. Furthermore, there is a lack of validated diagnostic tools and a poor predictive rationality of current therapeutic biomarkers. Hence, extensive and precise research is required to speed up the process of drug testing and development by the application of artificial intelligence technologies, structure‐based drug design, in‐silico approaches, and drug repurposing.
pharmacology & pharmacy